The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages.
The efficacy of antibody immunity against Streptococcus pneumoniae stems from the ability of opsonic, serotype (ST)-specific antibodies to pneumococcal capsular polysaccharide (PPS) to facilitate killing of the homologous ST by host phagocytes. However, PPS-specific antibodies have been identified that are protective in mice, but do not promote opsonic killing in vitro, raising the question of how they mediate protection in vivo. To probe this question, we investigated the dependence of antibody efficacy against lethal systemic (intraperitoneal, i.p.) infection with Streptococcus pneumoniae serotype 3 (ST3) on macrophages and neutrophils for the following PPS3-specific monoclonal antibodies (MAbs) in survival experiments in mice using a non-opsonic human IgM (A7), a non-opsonic mouse IgG1 (1E2) and an opsonic mouse IgG1 (5F6). The survival of A7- and PPS3-specific and isotype control MAb-treated neutrophil-depleted and neutrophil-sufficient and macrophage-depleted and macrophage-sufficient mice were determined after i.p. challenge with ST3 strains 6303 and WU2. Neutrophils were dispensable for A7 and the mouse MAbs to mediate protection in this model, but macrophages were required for the efficacy of A7 and optimal mouse MAb-mediated protection. For A7-treated mice, macrophage-depleted mice had higher blood CFU, cytokines and peripheral neutrophil levels than macrophage-sufficient mice, and macrophage-sufficient mice had lower tissue bacterial burdens than control MAb-treated mice. These findings demonstrate that macrophages contribute to opsonic and non-opsonic PPS3-specific MAb-mediated protection against ST3 infection by enhancing bacterial clearance and suggest that neutrophils do not compensate for the absence of macrophages in the model used in this study.
Fabrizio
Kevin
K
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Manix
Catherine
C
Tian
Haijun
H
van Rooijen
Nico
N
Pirofski
Liise-anne
LA
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D058491:Bacterial Load; D016207:Cytokines / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000276:immunology; D011008:Pneumococcal Infections / Q000276:immunology* / Q000517:prevention & control; D011135:Polysaccharides, Bacterial / Q000276:immunology*
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D016207:Cytokines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011135:Polysaccharides, Bacterial
Clin Vaccine Immunol. 2010 May;17(5):713-21
20200186
Infect Immun. 2009 Jan;77(1):464-71
19001076
Infect Immun. 2009 Jan;77(1):485-91
19001080
Infect Immun. 2007 Mar;75(3):1196-202
17210665
Eur J Immunol. 2007 Dec;37(12):3540-50
18000956
J Immunol. 1999 Feb 1;162(3):1685-91
9973430
J Clin Invest. 2006 Oct;116(10):2817-26
17016562
Infect Immun. 2005 Aug;73(8):4530-8
16040964
Infect Immun. 2010 Jul;78(7):3129-35
20439480
Clin Exp Immunol. 2005 May;140(2):230-40
15807846
J Immunol. 2008 Apr 1;180(7):4865-74
18354210
Infect Immun. 2002 Sep;70(9):4977-86
12183544
Infect Immun. 2002 Aug;70(8):4226-38
12117931
Rev Infect Dis. 1983 Sep-Oct;5 Suppl 4:S797-805
6356294
Trends Immunol. 2004 Mar;25(3):143-9
15036042
J Immunol. 2001 Apr 1;166(7):4604-11
11254718
J Exp Med. 1981 Mar 1;153(3):694-705
7252411
Clin Diagn Lab Immunol. 2000 Mar;7(2):314-7
10702513
Scand J Infect Dis. 2003;35(9):647-52
14620149
Infect Immun. 2007 Apr;75(4):1586-97
17296760
Clin Diagn Lab Immunol. 1997 Jul;4(4):415-22
9220157
J Infect Dis. 1980 Dec;142(6):903-9
7462698
Clin Vaccine Immunol. 2007 Apr;14(4):382-90
17301214
Nat Immunol. 2000 Nov;1(5):441-6
11062505
J Surg Res. 2011 May 15;167(2):e131-6
19691988
J Exp Med. 2007 Jun 11;204(6):1319-25
17548523
Infect Immun. 2009 Apr;77(4):1502-13
19168739
Nature. 2006 Nov 9;444(7116):217-20
17051150
Clin Diagn Lab Immunol. 1999 Jul;6(4):581-6
10391867
J Exp Med. 2004 Mar 1;199(5):717-23
14981111
J Immunol. 2008 May 1;180(9):6246-54
18424747
Cell. 2006 Mar 10;124(5):915-27
16530040
Mol Immunol. 2008 Oct;45(16):4041-7
18752851
J Immunol Methods. 1994 Sep 14;174(1-2):83-93
8083541
Infect Immun. 2007 Apr;75(4):1643-50
17220309
Infect Immun. 2005 Jan;73(1):114-25
15618146
Microb Pathog. 2004 Oct;37(4):169-75
15458777
Clin Vaccine Immunol. 2009 May;16(5):636-45
19279169
J Immunol. 2005 Sep 1;175(5):3244-51
16116215
J Immunol. 2004 Mar 1;172(5):3132-8
14978119
Innate Immun. 2009 Feb;15(1):3-12
19201820
Immunity. 1999 Oct;11(4):443-51
10549626
Am J Respir Crit Care Med. 2003 Jan 15;167(2):171-9
12406830
Clin Vaccine Immunol. 2006 Feb;13(2):165-9
16467321
Antimicrob Agents Chemother. 1993 Feb;37(2):234-9
8452353
Eur J Immunol. 2009 Apr;39(4):1147-56
19266484
Clin Vaccine Immunol. 2006 Apr;13(4):459-66
16603613
J Clin Invest. 2009 Jul;119(7):1899-909
19509469
Nature. 1981 Nov 5;294(5836):88-90
6170000
Infect Immun. 1999 Sep;67(9):4517-24
10456894